Cyclopharm (ASX:CYC) received an additional installation purchase order from a US Department of Veterans Affairs hospital for its Technegas product after its deployment under the Federal Supply
Schedule, according to a Tuesday Australian bourse filing.
Technegas is a structured ultra-fine dispersion of radioactive labelled carbon, which allows for views and tomography imaging under a gamma or single photon emission computed tomography camera.
Its sales receipts in the US exceeded $1 million since commercial sales began last year. Its US installed base as of March 31 reached 27 technegas systems, from 17 systems as of Dec. 31, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.